Obstet Gynecol

ACOG calls for universal cannabis screening in pregnancy and postpartum

September 24, 2025

The American College of Obstetricians and Gynecologists (ACOG) has released a new clinical consensus on Cannabis Use During Pregnancy and Lactation, recommending universal screening during the prepregnancy, pregnancy, and postpartum periods. The updated guidance responds to rising cannabis use among reproductive-aged individuals and growing misperceptions about its safety.

Cannabis use in pregnancy is associated with spontaneous preterm birth, low birth weight, NICU admission, and long-term neurodevelopmental risks. ACOG emphasizes that there are no medical indications for cannabis use during pregnancy or lactation.

Screening should be conducted via interview, self-report, or validated tools, not biologic testing, which may be inaccurate and contribute to racial disparities. Clinicians are urged to obtain informed consent before any drug testing and to be aware of local policies that may trigger child protective services involvement.

Importantly, continued cannabis use isn't a contraindication to breastfeeding, and patients should be supported in their feeding decisions while minimizing exposure risks. The guidance encourages motivational interviewing and tailored interventions to reduce use and promote maternal–infant health.

Sources:

(2025, September 18). Obstet Gynecol. Cannabis use during pregnancy and lactation. Clinical Consensus No. 10. https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2025/10/cannabis-use-during-pregnancy-and-lactation

(2025, September 19). American College of Obstetricians and Gynecologists. ACOG Releases New Recommendations on Cannabis Use in Pregnancy and Lactation. [Press release]. https://www.acog.org/news/news-releases/2025/09/acog-releases-new-recommendations-cannabis-use-pregnancy-lactation